Myasthenia Gravis Inebilizumab Trial
Public ClinicalTrials.gov record NCT04524273. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.
Study identification
- NCT ID
- NCT04524273
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 238 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2020 (Actual)
- Primary completion
- May 28, 2024 (Actual)
- Completion
- Jun 7, 2029 (Estimated)
- Last update posted
- May 15, 2026
2020 – 2029
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Viela Bio Investigative Site - 1015 | Orange | California | 92868 | — |
| Viela Bio Investigative Site - 1002 | New Haven | Connecticut | 06519 | — |
| Viela Bio Investigative Center - 1024 | Washington D.C. | District of Columbia | 20010 | — |
| Viela Bio Investigative Site - 1005 | Tampa | Florida | 33612 | — |
| Viela Bio Investigative Site - 1012 | Kansas City | Kansas | 66160 | — |
| Viela Bio Investigative Site - 1018 | Charlotte | North Carolina | 28203 | — |
| Viela Bio Investigative Site - 1025 | Canton | Ohio | 44718 | — |
| Viela Bio Investigative Site - 1001 | Cincinnati | Ohio | 45219 | — |
| Viela Bio Investigative Site - 1009 | Columbus | Ohio | 43210 | — |
| Viela Bio Investigative Site - 1008 | Pittsburgh | Pennsylvania | 15212 | — |
| Viela Bio Investigative Site - 1019 | Austin | Texas | 78759 | — |
| Viela Bio Investigative Site - 1003 | Houston | Texas | 77030 | — |
| Viela Bio Investigative Site - 1014 | San Antonio | Texas | 78229 | — |
| Viela Bio Investigative Site - 1017 | Salt Lake City | Utah | 84132 | — |
| Viela Bio Investigative Site - 1004 | Burlington | Vermont | 05401 | — |
| Viela Bio Investigative Site - 1006 | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04524273, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 15, 2026 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04524273 live on ClinicalTrials.gov.